Victory Capital Management Inc. Has $20.28 Million Stake in Balchem Co. (NASDAQ:BCPC)

Victory Capital Management Inc. boosted its stake in Balchem Co. (NASDAQ:BCPC - Free Report) by 25.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,413 shares of the basic materials company's stock after acquiring an additional 25,560 shares during the quarter. Victory Capital Management Inc. owned 0.38% of Balchem worth $20,279,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in shares of Balchem by 1.0% in the third quarter. State Street Corp now owns 1,234,226 shares of the basic materials company's stock valued at $217,224,000 after purchasing an additional 12,006 shares in the last quarter. Geode Capital Management LLC lifted its stake in Balchem by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 928,904 shares of the basic materials company's stock valued at $163,514,000 after acquiring an additional 27,979 shares in the last quarter. Geneva Capital Management LLC lifted its stake in Balchem by 1.7% in the 3rd quarter. Geneva Capital Management LLC now owns 779,869 shares of the basic materials company's stock valued at $137,257,000 after acquiring an additional 12,750 shares in the last quarter. FMR LLC boosted its position in Balchem by 944.3% during the 3rd quarter. FMR LLC now owns 497,495 shares of the basic materials company's stock worth $87,559,000 after acquiring an additional 449,854 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Balchem by 1.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company's stock worth $80,782,000 after acquiring an additional 7,721 shares in the last quarter. 87.91% of the stock is owned by institutional investors and hedge funds.

Balchem Trading Down 0.8 %

Shares of Balchem stock opened at $169.20 on Wednesday. The stock has a market cap of $5.50 billion, a P/E ratio of 43.05, a P/E/G ratio of 4.41 and a beta of 0.63. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19. Balchem Co. has a 12-month low of $137.69 and a 12-month high of $186.03. The business's 50 day moving average is $163.30 and its 200-day moving average is $169.86.

Remove Ads

Balchem (NASDAQ:BCPC - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.11 by ($0.08). Balchem had a return on equity of 11.37% and a net margin of 13.47%. The firm had revenue of $240.00 million for the quarter, compared to the consensus estimate of $239.96 million. Equities research analysts predict that Balchem Co. will post 4.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BCPC shares. Sidoti raised shares of Balchem to a "hold" rating in a research report on Tuesday, February 25th. StockNews.com cut shares of Balchem from a "buy" rating to a "hold" rating in a research report on Tuesday, February 25th. Finally, HC Wainwright restated a "buy" rating and issued a $190.00 price objective on shares of Balchem in a report on Monday, February 24th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.